Carbylan Therapeutics Inc  

(Public, NASDAQ:CBYL)   Watch this stock  
Find more results for David McKune
5.43
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.68 - 9.22
Open     -
Vol / Avg. 0.00/56,610.00
Mkt cap 142.93M
P/E     -
Div/yield     -
EPS -1.28
Shares 15.25M
Beta     -
Inst. own 164%
Aug 12, 2015
Carbylan Therapeutics Inc at Wedbush PacGrow Healthcare Conference - Webcast
Aug 11, 2015
Q2 2015 Carbylan Therapeutics Inc Earnings Call - Webcast
Aug 11, 2015
Q2 2015 Carbylan Therapeutics Inc Earnings Release
Jun 23, 2015
Carbylan Therapeutics, Inc. at the JMP Securities 2015 Life Sciences Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -128742.90% -46065.52%
Operating margin -80957.14% -40265.52%
EBITD margin - -40079.31%
Return on average assets -96.00% -159.52%
Return on average equity -698.16% -
Employees 14 -
CDP Score - -

Address

3181 Porter Dr
PALO ALTO, CA 94304-1213
United States - Map
+1-650-8556777 (Phone)
+1-650-8559119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Carbylan Therapeutics, Inc. (Carbylan Therapeutics) is a clinical-stage specialty pharmaceutical company. The Company is focused on the development and commercialization of combination therapies that address unmet medical needs. The Company’s focus is on the development of Hydros-TA, an intra-articular (IA), injectable product candidate to treat pain associated with osteoarthritis (OA), of the knee. Hydros-TA utilizes cross-linking technology to deliver both rapid pain relief with a low dose corticosteroid triamcinolone acetonide, (TA), and sustained pain relief from hyaluronic acid viscosupplement. It is comprised of bacterially-derived HA-based hydrogel particles suspended in a solution of hyaluronic acid. Hydros-TA is being studied in its COR1.1 trial, a Phase III, multi-center, randomized, double-blind, three-arm trial with grade two and grade three OA of the knee.

Officers and directors

David Renzi President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
John McKune Principal Accounting Officer, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Marcee Maroney Vice President - Clinical Affairs and Marketing
Age: 45
Bio & Compensation  - Reuters
Hayley Lewis Vice President - Regulatory Affairs & Quality Assurance
Age: 39
Bio & Compensation  - Reuters
Premchandran Ramiya Vice President - Pharmaceutical Development & Supply Chain
Bio & Compensation  - Reuters
David M. Gravett Ph.D. Vice President - Research & Development
Age: 48
Bio & Compensation  - Reuters
Steven L. Basta Independent Director
Age: 48
Bio & Compensation  - Reuters
Albert Cha M.D., Ph.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
David M. Clapper Independent Director
Age: 63
Bio & Compensation  - Reuters
Keith A. Katkin Independent Director
Age: 43
Bio & Compensation  - Reuters